ClinicalTrials.gg
CompletedNCT06601322FOCUS-RightUpdated Aug 12, 2026

Functional Outcomes in CondUction System Pacing and Right Ventricular Synchrony (FOCUS-Right)

An interventional study of Pacemaker Interrogation and Electrocardiogram (ECG): and Cardiopulmonary Exercise Test (CPET) and Exercise Stress Cardiac Magnetic Resonance (ExeCMR in Left Branch Bundle Block and RV - Right Ventricular Abnormality, sponsored by Virginia Commonwealth University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Virginia Commonwealth University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this prospective single center clinical trial is to evaluate the safety and feasibility of performing simultaneous exercise stress cardiac magnetic resonance (CPET-CMR) and cardiopulmonary exercise testing in patients with pre-existing left bundle branch area pacemakers (LBBAP) programmed to an atrial sensing mode. Measurements of right ventricular, left ventricular function, and exercise capacity will be obtained at various LBBAP programming parameters at rest and during low intensity exercise. The main aims of the study are:

  • Demonstrate the safety and feasibility of performing CPET-CMR in patients with pre-existing LBBAP programmed to P-synchronous ventricular pacing mode.
  • Generate preliminary data evaluating differences in RV function, LV function, and exercise capacity during various pacemaker programming settings.
Read the detailed description

Conduction system pacing, namely left bundle branch area pacing (LBBAP) represents an important pacing modality introduced to avoid the deleterious effects of non-physiologic ventricular activation during chronic right ventricular pacing and /or left bundle branch block (LBBBP). Previous studies have demonstrated that LBBAP exhibits similar or superior left ventricular resynchronization compared to conventional treatment modalities, the impact of this novel pacing strategy on the right ventricle has not yet been addressed. This study aims to demonstrate the safety and feasibility of assessing LBBAP performance with a focus on right ventricular function in a novel way utilizing Cardiopulmonary Exercise Testing and Exercise Stress Cardiac Magnetic Resonance.

The investigators plan a 1-day prospective non-randomized controlled pilot study in which up to 20 subjects with left bundle branch area pacemakers with evidence of output dependent anodal capture will undergo low intensity exercise CPET-CMR at three different LBBAP settings (underlying rhythm, non-selective left bundle pacing, non-selective left bundle pacing with anodal stimulation).

02

Conditions studied

  • Left Branch Bundle Block
  • RV - Right Ventricular Abnormality

Browse trials for

Keywords

  • Pacemaker
  • CPET-CMR
03

In context

Bundle-Branch Block

94 studies on the registry are indexed under Bundle-Branch Block; 30 are open to participants now.

This study's enrollment of 5 is below the median of 60 across 59 interventional studies indexed under Bundle-Branch Block.

Browse Bundle-Branch Block studies →

Lead sponsor

Virginia Commonwealth University is the lead sponsor of 648 studies on the registry; 80 are open to participants now.

Of its 90 completed or terminated interventional studies of FDA-regulated products, 64 (71%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • presence of dual chamber LBBAP implantation
  • presence of anodal capture with bipolar pacing configuration as determined at pacing implant.

Exclusion criteria

Exclusion Criteria:

  • Known history of chronotropic incompetence
  • high degree or complete heart block
  • inability to tolerate NVP during initial device interrogation
  • pregnancy
  • inability to undergo MRI or exercise utilizing supine bicycle at target work-load
  • presence of MRI unsafe pacemaker components.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Other
    No Ventricular Pacing (NVP)

    Assessment 1 (No Ventricular Pacing) will be performed with no ventricular pacing to assess baseline right and left ventricular function at rest and during exercise.

    Other: Pacemaker Interrogation and Electrocardiogram (ECG): · Other: Cardiopulmonary Exercise Test (CPET) and Exercise Stress Cardiac Magnetic Resonance (ExeCMR · Other: Continuous pacemaker telemetry (CPT)

  • Active comparator
    Non-selective or Selective Left Bundle Branch Area Pacing (nsLBBAP)

    Phase 2 (non-selective or selective Left Bundle Branch Area Pacing or ns/sLBBAP) will assess right and left ventricular function at rest and during exercise with non-selective or selective left bundle branch area pacing

    Other: Pacemaker Interrogation and Electrocardiogram (ECG): · Other: Cardiopulmonary Exercise Test (CPET) and Exercise Stress Cardiac Magnetic Resonance (ExeCMR · Other: Continuous pacemaker telemetry (CPT)

  • Experimental
    Left Bundle Branch Area Pacing with Anodal Capture (aLBBAP)

    Phase 3 (Left Bundle Branch Area Pacing with Anodal Capture or aLBBAP) will assess right and left ventricular function at rest and during exercise with left bundle branch area pacing with anodal capture.

    Other: Pacemaker Interrogation and Electrocardiogram (ECG): · Other: Cardiopulmonary Exercise Test (CPET) and Exercise Stress Cardiac Magnetic Resonance (ExeCMR · Other: Continuous pacemaker telemetry (CPT)

Interventions

  • OtherPacemaker Interrogation and Electrocardiogram (ECG):

    Prior to the CMR study, subjects will undergo baseline interrogation of their dual chamber LBBAP to assess for appropriate device function. Lead capture characteristics will then be assessed with continuous intracardiac electrogram characteristics recorded from the atrial and ventricular lead with simultaneous 12-lead ECG rhythm strip recordings to assess for settings at which the investigators can differentiate aLBBAP, sLBBAP and nsLBBAP. Pacing output will be increased until left bundle branch area pacing with anodal capture is achieved, and then decreased until anodal capture is lost. These programming parameters will be recorded and utilized for Phase 2-3 of the CPET-CMR scan. 12-lead ECG rhythm strips of QRS morphology with each parameter set will be obtained and saved for later analysis.

  • OtherCardiopulmonary Exercise Test (CPET) and Exercise Stress Cardiac Magnetic Resonance (ExeCMR

    Following ECG and pacemaker analysis as above for safety, subjects will be fitted with 2 sets of MRI-compatible ECG monitoring systems a BP monitoring system , and a finger-tip pulse gating system. Imaging will be performed on a Magnetom Vida 3 Tesla scanner by trained CRM radiology technologists.

  • OtherContinuous pacemaker telemetry (CPT)

    CPT will be established and supervised by a cardiac electrophysiologist to monitor for evidence of noise or artifact which may lead to inability to appropriately sense native atrial depolarization in DDD mode. Subjects with PM dependence are excluded. If noise is noted during scanning with NVP, then scanning will NOT be performed during P-synchronous pacing and will instead be performed during overdrive pacing at a rate above the patients maximal achieved heart rate with exertion during Phase 1. Thus, there is minimal risk to the subject from PM programming during CPET-CMR.

06

What researchers measure

Primary outcomes

  1. Incidence of Pacemaker Atrial (P Wave) Over-Sensed Events

    Incidence of pacemaker atrial (P Wave) over sensing as derived from continuous pacemaker telemetry at optimal programmed atrial sensitivity.

    Time frame: Day 1: From beginning of CPET-CMR imaging procedure to end of CPET-CMR imaging procedure on study day.

Secondary outcomes

  1. Incidence of Pacemaker Atrial (P Wave) Under-Sensed Events

    Incidence of pacemaker atrial (P Wave) under sensing as derived from continuous pacemaker telemetry at optimal programmed atrial sensitivity.

    Time frame: Day 1: From beginning of CPET-CMR imaging procedure to end of CPET-CMR imaging procedure on study day.

  2. Left Ventricular Ejection Fraction (%)

    Left ventricular ejection fraction (%) as measured by cardiac magnetic resonance imaging.

    Time frame: Day 1: From beginning of CPET-CMR imaging procedure to end of CPET-CMR imaging procedure on study day.

  3. Right Ventricular Ejection Fraction (%)

    Right ventricular ejection fraction (%) as measured by cardiac magnetic resonance imaging.

    Time frame: Day 1: From beginning of CPET-CMR imaging procedure to end of CPET-CMR imaging procedure on study day.

Other outcomes

  1. Slope of VO2 as a Function of Work Rate

    Slope of VO2 as a function of work rate as quantified by cardiopulmonary exercise testing.

    Time frame: Day 1: From beginning of CPET-CMR imaging procedure to end of CPET-CMR imaging procedure on study day.

07

Study locations

1 site
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2024 to primary completion in May 2025, 8 months.

Of 32 interventional studies with no phase under Bundle-Branch Block, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 61. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2024
First posted
Sep 19, 2024
StartActual
Aug 23, 2024
Primary completionActual
May 13, 2025
CompletionActual
May 13, 2025
Last update
Aug 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06601322
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Aug 23, 2024
Primary completion
May 13, 2025
Completion
May 13, 2025
Last update
Aug 12, 2026

Study contacts

Ajay Pillai
principal investigator · Virginia Commonwealth University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion